Navigation Links
Monogram Announces Conference Call
Date:10/23/2008

LEADING HIV PHYSICIAN, Dr. DAVID HARDY, TO DISCUSS CLINICAL USE OF THE TROFILE(TM) ASSAY AND SELZENTRY(TM) IN CONJUNCTION WITH THE THIRD QUARTER

2008 FINANCIAL RESULTS CONFERENCE CALL

SOUTH SAN FRANCISCO, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc., (Nasdaq: MGRM) announced that it will hold a conference call on Monday, October 27, 2008 at 4:30 p.m. (Eastern Time) to discuss the clinical use of Monogram's Trofile(TM) Assay in conjunction with Pfizer's CCR5 antagonist, Selzentry(TM). Monogram will also review its third quarter 2008 financial results. The call will be hosted by William D. Young, Chairman & CEO of Monogram. Dr. David Hardy will participate in the call. Dr. Hardy is Director, Division of Infectious Diseases at Cedars-Sinai Medical Center and is Associate Professor of Medicine-in-Residence at the David Geffen School of Medicine at UCLA.

To participate in the live teleconference, please call (877) 604-9672, or (719) 325-4896 for international callers, fifteen minutes before the conference begins. Live audio of the call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public. Access to live and archived audio of the conference call will be available on the Investor Relations section at http://www.monogrambio.com. Following the live broadcast, a replay of the call will also be available at (888) 203-1112 or (719) 457-0820 for international callers, through Sunday, November 9, 2008. The replay passcode is 4461917. The information provided on the teleconference is only accurate at the time of the conference call, and Monogram will take no responsibility for providing updated information except as required by law.

About Monogram Biosciences, Inc.

Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved anti-viral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at http://www.monogrambio.com.

Trofile is a trademark of Monogram Biosciences, Inc. Selzentry is a trademark of Pfizer Inc.

contacts: Alfred G. Merriweather Jeremiah Hall

Chief Financial Officer Feinstein Kean Healthcare

Tel: 650 624-4576 Tel: 415 677-2700

amerriweather@monogrambio.com jeremiah.hall@fkhealth.com


'/>"/>
SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Monogram Receives NASDAQ Notification
2. Monogram and Dana-Farber Cancer Institute Initiate Evaluation of HERmark(TM) Breast Cancer Assay in Metastatic Breast Cancer
3. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
4. Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors
5. Monogram Biosciences Announces Second Quarter 2008 Financial Results Conference Call
6. Monogram Biosciences to Present at the Collins Stewart Fourth Annual Growth Conference
7. Sensitivity Enhancements to Monograms Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
8. Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting
9. Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting
10. Monogram Biosciences Announces First Quarter 2008 Financial Results Conference Call
11. Monogram Biosciences to Present at the JMP Securities Seventh Annual Research Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... ... eye wash is a basic first aid supply for any work environment, but most personal ... rinse first if a dangerous substance enters both eyes? It’s one less decision, and likely ... dual eye piece. , “Whether its dirt and debris, or an acid or alkali, getting ...
(Date:10/11/2017)... 11, 2017  VMS BioMarketing, a leading provider of patient ... Clinical Nurse Educator (CNE) network, which will launch this week. ... among health care professionals to enhance the patient care experience ... and other health care professionals to help women who have ... ...
(Date:10/11/2017)... TX (PRWEB) , ... October 11, 2017 , ... ... August compared the implantation and pregnancy rates in frozen and fresh in ... contribution of progesterone and maternal age to IVF success. , After comparing the ...
(Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
Breaking Biology Technology:
(Date:3/30/2017)... LOS ANGELES , March 30, 2017  On ... Hack the Genome hackathon at ... This exciting two-day competition will focus on developing health ... experience. Hack the Genome is ... has been tremendous. The world,s largest companies in the ...
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. Mohamed ... received the prestigious international IAIR Award for the most innovative high security ... ... Maldives Immigration Controller General, ... picture on the right) have received the IAIR award for the "Most ...
Breaking Biology News(10 mins):